Literature DB >> 21349838

Human umbilical cord blood-derived stromal cells, a new resource in the suppression of acute graft-versus-host disease in haploidentical stem cell transplantation in sublethally irradiated mice.

Cheng Zhang1, Xing-Hua Chen, Xi Zhang, Lei Gao, Pei-Yan Kong, Xian-gui Peng, Xue Liang, Li Gao, Yi Gong, Qing-Yu Wang.   

Abstract

Human umbilical cord blood-derived stromal cells (hUCBDSCs), a novel population isolated from CD34(+) cells by our laboratory, exerted an immunosuppressive effect on xenogenic T cells. This study aimed to investigate whether hUCBDSCs play a critical role in the suppression of acute graft-versus-host disease (aGVHD). The hUCBDSCs were co-cultured with splenocytes (SPCs) of donor C57BL/6 mice. The aGVHD in the recipient (B6×BALB/c) F1 mice was induced by the infusion of bone marrow cells and SPCs from donor mice following sublethal irradiation. The shift in vivo for hUCBDSCs was detected. The proliferation and cell cycle of SPCs were tested by cell counting kit-8 and flow cytometry, respectively. The expression of CD49b natural killer (NK) cells and CD3 T cells was detected by flow cytometry in co-culture and post-transplantation. IL-4, and IFN-γ were detected by ELISA in the serum of co-culture and post-transplantation. The survival time, body weight, clinical score, and histopathological score were recorded for mice post-transplantation. The hUCBDSCs promoted the proliferation of SPCs and significantly increased the ratio of the S and G(2)/M phase (p < 0.05). The hUCBDSCs significantly increased the expression of CD49b NK cells and IL-4 protein and decreased the expression of CD3 T cells and IFN-γ protein both in vitro and in vivo. The survival time of mice with co-transplantation of hUCBDSCs was significantly prolonged, and decreased clinical and histopathological scores were also observed. The hUCBDSCs were continually detected in the target organs of GVHD. These results suggest that hUCBDSCs possess the capability of suppressing aGVHD, possibly via their influence on CD3 T cells, NK cells, and cytokines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21349838      PMCID: PMC3075716          DOI: 10.1074/jbc.M110.144691

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation.

Authors:  Loredana Ruggeri; Antonella Mancusi; Emanuela Burchielli; Marusca Capanni; Alessandra Carotti; Teresa Aloisi; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Blood Cells Mol Dis       Date:  2007-10-26       Impact factor: 3.039

Review 2.  Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: a review.

Authors:  Liang-Piu Koh; Nelson J Chao
Journal:  Blood Cells Mol Dis       Date:  2007-09-19       Impact factor: 3.039

Review 3.  Prophylaxis of acute GVHD: manipulate the graft or the environment?

Authors:  A John Barrett; Katarina Le Blanc
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

Review 4.  GVHD pathophysiology: is acute different from chronic?

Authors:  Tomomi Toubai; Yaping Sun; Pavan Reddy
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

Review 5.  Current and novel therapies in acute GVHD.

Authors:  Vincent T Ho; Corey Cutler
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

6.  IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation.

Authors:  C-K Min; B-G Kim; G Park; Bin Cho; I-H Oh
Journal:  Bone Marrow Transplant       Date:  2007-03-19       Impact factor: 5.483

7.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

Authors:  Katarina Le Blanc; Francesco Frassoni; Lynne Ball; Franco Locatelli; Helene Roelofs; Ian Lewis; Edoardo Lanino; Berit Sundberg; Maria Ester Bernardo; Mats Remberger; Giorgio Dini; R Maarten Egeler; Andrea Bacigalupo; Willem Fibbe; Olle Ringdén
Journal:  Lancet       Date:  2008-05-10       Impact factor: 79.321

8.  Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease.

Authors:  V Tisato; K Naresh; J Girdlestone; C Navarrete; F Dazzi
Journal:  Leukemia       Date:  2007-07-12       Impact factor: 11.528

9.  Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation.

Authors:  Lynne M Ball; Maria Ester Bernardo; Helene Roelofs; Arjan Lankester; Angela Cometa; R Maarten Egeler; Franco Locatelli; Willem E Fibbe
Journal:  Blood       Date:  2007-07-16       Impact factor: 22.113

10.  Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation.

Authors:  Astrid Schulze; Holger Schirutschke; Uta Oelschlägel; Marc Schmitz; Monika Füssel; Ralf Wassmuth; Gerhard Ehninger; Martin Bornhäuser; Uwe Platzbecker
Journal:  Exp Hematol       Date:  2008-02-08       Impact factor: 3.084

View more
  7 in total

1.  Ginsenoside Rg1 protects human umbilical cord blood-derived stromal cells against tert-Butyl hydroperoxide-induced apoptosis through Akt-FoxO3a-Bim signaling pathway.

Authors:  Ying Liu; Long Yi; Lu Wang; Linbo Chen; Xiongbin Chen; Yaping Wang
Journal:  Mol Cell Biochem       Date:  2016-08-13       Impact factor: 3.396

Review 2.  Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance.

Authors:  Cheng Zhang; Xi Zhang; Xing-Hua Chen
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

3.  Reconstruction of hematopoietic inductive microenvironment after transplantation of VCAM-1-modified human umbilical cord blood stromal cells.

Authors:  Yao Liu; Xing-hua Chen; Ying-jian Si; Zhong-jun Li; Lei Gao; Li Gao; Cheng Zhang; Xi Zhang
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

Review 4.  Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go.

Authors:  Meng Lv; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2012-03-18       Impact factor: 17.388

Review 5.  Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.

Authors:  Jun Liu; Jiang F Zhong; Xi Zhang; Cheng Zhang
Journal:  J Hematol Oncol       Date:  2017-01-31       Impact factor: 17.388

6.  Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cells.

Authors:  Cheng Zhang; Xi Zhang; Shi-Jie Yang; Xing-Hua Chen
Journal:  Oncol Lett       Date:  2017-02-07       Impact factor: 2.967

7.  Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models.

Authors:  Li Wang; Haiyan Zhang; Lixun Guan; Shasha Zhao; Zhenyang Gu; Huaping Wei; Zhe Gao; Feiyan Wang; Nan Yang; Lan Luo; Yonghui Li; Lili Wang; Daihong Liu; Chunji Gao
Journal:  Oncotarget       Date:  2016-09-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.